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Abstract
Chimeric virus-like particles (VLPs) were developed as a candidate for allergen-specific immunotherapy. In this study, hepatitis
B core antigen (HBcAg) that genetically fused to Chenopodium album polcalcin (Che a 3)–derived peptide was expressed in
E. coli BL21, purified, and VLP formation was evaluated using native agarose gel electrophoresis (NAGE) and transmission
electron microscopy (TEM). Chimeric HBc VLPs were characterized in terms of their reactivity to IgE, the induction of blocking
IgG and allergen-specific IgE, basophil-activating capacity, and Th1-type immune responses. Results from IgE reactivity and
basophil activation test showed that chimeric HBcVLPs lack IgE-binding capacity and basophil degranulation activity. Although
chimeric HBc VLPs induced the highest level of efficient polcalcin-specific IgG antibody in comparison to those induced by
recombinant Che a 3 (rChe a 3) mixed either with HBc VLPs or alum, they triggered the lowest level of polcalcin-specific IgE in
mice following immunization. Furthermore, in comparison to the other antigens, chimeric HBc VLPs produced a polcalcin-
specific Th1 cell response. Taken together, genetically fusion of allergen derivatives to HBc VLPs, in comparison to a mix of
them, may be a more effective way to induce appropriate immune responses in allergen-specific immunotherapy.
Key points
• The insertion of allergen-derived peptide into major insertion region (MIR) of hepatitis B virus core (HBc) antigen resulted in
nanoparticles displaying allergen-derived peptide upon its expression in prokaryotic host.
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• Chimeric HBc VLPs dramatically improved protective IgG antibody response compared with those induced by allergen mixed
either with HBc VLPs or alum.
• Chimeric HBc VLPs induced Th1 responses that were counterparts of Th2 responses (allergic).
• Chimeric HBc VLPs increased IgG2a/ IgG1 ratio and the level of IFN-γ compared to those induced by allergen mixed with
either HBc VLPs or alum.
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Introduction
Type I allergy as a health problem affects up to 20–30% of the
population in industrialized countries (Ghasemi et al. 2020).
Allergen-specific immunotherapy (AIT), that includes the
continuous oral (Pajno et al. 2014), sublingual, or subcutane-
ous administration of allergenic food or extract, is known as
the only disease-modifying treatment of IgE-mediated aller-
gies (Komlósi et al. 2020; Narisety and Keet 2012). The
mechanism of successful AIT has not been fully elucidated.
Nevertheless, a shift from Th2 toward Th1 responses or the
engagement of regulatory T (Treg) cells, in order to reduce the
recruitment of key cells in the progression of allergic disorders
(e.g., basophils and mast cells), are known hallmark indicators
of successful AIT (Ai et al. 2015; Ren et al. 2014). However,
the efficacy and broad applicability of AIT is limited due to
the disadvantages, such as time-consuming, costly physician’s
visits, the requirement for numerous and frequent injections,
(Hedlin et al. 1991; Winther et al. 2006), low response effi-
ciency, the potential for life-threatening (anaphylactic) reac-
tions, and new sensitizations to non-allergenic proteins pres-
ent in the extract (Burks et al. 2013; Valenta 2002). The iden-
tification and characterization of the disease-causing allergens
by immunoblotting and molecular cloning techniques can
lessen the variation of the quality and quantity of desired or
undesired allergens in crude extracts and AIT-immediate side
effects (Oliveira et al. 2010). Furthermore, manipulating the
amino acid sequence of allergens to generate hypoallergens
can reduce IgE-mediated side effects such as anaphylaxis
shock (Ai et al. 2015). It has been established that blocking
IgG antibodies (e.g., IgG4) prevents IgE binding to the aller-
gen; thus applying hypoallergenic allergen derivatives in AIT,
instead of intact allergens, can alleviate allergic symptoms
(Bannon et al. 2001; Linhart and Valenta 2005; Valenta and
Kraft 2002). In this way, utilization of efficient delivery plat-
forms such as virus-like particles (VLPs) may be an effective
strategy to increase the allergen-specific immunotherapy
(AIT) efficacy, meanwhile, decrease the time course and cost
of the treatment and the number of injections, by improving
humoral immune response and establishing a balance between
Th1 and Th2 response (Curin et al. 2018; Swoboda et al.
2002; Valenta and Kraft 2002).
Virus-like particles are an excellent and attractive platform
for epitope presentation that induces robust immunogenic re-
sponses due to their multivalent, highly repetitive structure
(Mohan et al. 2017; Wang et al. 2012). Hepatitis B core anti-
gen (HBcAg) can self-assemble into highly immunogenic
VLP particles when expressed in prokaryotic host expression
systems, and exogenous peptide can locate at the tips of sur-
face spike of HBc VLP expressed in bacteria when inserted
into the major insertion region (MIR) of HBc VLP. The major
insertion region is the most immunodominant site exposed on
the surface of HBc VLPs. The insertion of foreign antigen into
this site via genetic fusion can generate recombinant chimeric
HBc particles, decorated with the inserted antigen, that can
preferably induce a strong antibody response against the
inserted antigen (Guo et al. 2019; Peyret et al. 2015). The
encapsidation of nucleic acid compounds (DNA, RNA) from
bacterial host into the VLP during VLP formation process
inside bacteria induces TLR7/8- and 9-mediated interferon-
alpha (IFN-α) secretion from dendritic cells that suppress
Th2 responses (Huber et al. 2010; Mohsen et al. 2020), while
skewing the immune response toward a Th1 response, which
is a desired response in successful AIT (Anzaghe et al. 2018;
Sominskaya et al. 2013; Storni et al. 2020). Researchers have
applied VLPs in different ways for allergy treatment. Some of
them have used CpG-encapsulated VLP either alone or mixed
with allergen extract in order to induce general Th1 response
in allergic diseases (Beeh et al. 2013; Klimek et al. 2011; Senti
et al. 2009), or chemically conjugated it to allergen-derived
peptide to produce allergen-specific IgG antibodies (Kündig
et al. 2006). However, further evaluation is needed onwhether
mixing VLP with allergen or allergen derivatives is sufficient
for inducing the desired immune response or if conjugation of
VLPs to allergen is a better approach. In the current study,
chimeric HBc VLP (displaying a hypoallergenic allergen-
derived peptide) was produced, and its ability to induce the
desired immune response was then compared to those induced
by allergen mixed with either alum or HBc VLPs. To this aim,
the Chenopodium album polcalcin (Che a 3) attributed to two
EF-hand allergens (Verdino et al. 2008) was used as an aller-
gen model for the following reasons that it is a potent aller-
genic protein, has high cross-reactivity with pollens of various
plants (trees, bushes, grasses, weeds, and flowering plants)
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(Ledesma et al. 2006; Tinghino et al. 2002), and is the most
commonly recognized allergen by chenopod pollen–
sensitized patients (Barderas et al. 2003; Hauser et al. 2010;
Verdino et al. 2008). Therefore, HBc VLP, which is the most
common and preferred VLP to display antigen through genet-
ic fusion (Oliveira et al. 2005; Pumpens et al. 1995; Schödel
et al. 1996), was used to generate chimeric HBc VLPs
displaying a hypoallergenic allergen-derived peptide.
Due to the low insertion capacity of MIR-HBc for foreign
antigen, it was impossible to insert full-length of Che a 3 into
MIR (Pumpens and Grens 2001). Hence, according to the
study of Westritschnig, K et al. (Westritschnig et al. 2004),
the C-terminal half segment of Che a 3 (called as C. Che a 3)
was selected as hypoallergenic Che a 3 derivative and was
genetically fused to MIR on the HBcAg to produce VLP pre-
senting C. Che a 3 (chimeric HBc VLP). Evaluation of im-
mune responses in immunized mice revealed that chimeric
HBc VLP was more potent than the other combination treat-
ments (allergen + HBc VLP/alum) to drive the immune re-
sponses (i.e., allergen-specific IgG, Th1 response) in favor of
allergy immunotherapy (Smarr et al. 2013).
Materials and methods
Plasmid construction and expression of chimeric HBc
VLP
Recombinant CoHBc plasmid containing HBc antigen (MW
~ 20.9 kDa) coding nucleotide sequence from hepatitis B virus
(HBV320 genome, genotype D1, subtype ayw2, GenBank
accession number X02496) was kindly gifted from professor
David Rowlands (University of Leeds). This construct con-
tains restriction sites (EcoRI and Nhe I restriction enzymes)
that were placed in the MIR loop (S. data 1). Gene-encoding
C-terminal half (aa: 45–86) of Che a 3 (accession No:
AY082338.1) plus GGGGS linker at both ends with recogni-
tion site of restriction enzymes EcoRI/NheI at the 3′ and 5′ end
(MW ~ 5.72 kDa) was synthesized (Pepmic Co., China).
Then, the CoHBc plasmid and synthesized gene were digested
with EcoR1/Nhel; subsequently, the digested gene was
inserted into MIR sit of HBc to construct chimeric HBc
(MW ~ 26.62 kDa) (accession number: MT625678) (Fig.
1a, d). The accuracy of nucleotide sequence of resultant re-
combinant plasmid was confirmed through restriction enzyme
mapping and Sanger sequencing method. The structure of
chimeric HBc protein was predicted via submitting its amino
acid sequence in the ITASSER server (https://zhanglab.ccmb.
med.umich.edu/I-TASSER/) (Fig. 1d).
To perform the cloning of chimeric HBc plasmid, E. coli
TOP10 cells (Invitrogen) were transformed by chimeric HBc
plasmid, and a positive clone was selected on Luria-Bertani
(LB) agar containing 50 μg/ml kanamycin. For expression,
the E. coli Bl21 strain (DE3) (Invitrogen) was transformed
by chimeric HBc plasmid or CoHBc plasmid, and expression
was induced by adding IPTG (Sigma-Aldrich, Germany) to
the final concentration of 0.2 mmol/l for 20 h at 18 °C. For
evaluation of protein expression, the bacterial cells (optical
density at 600 nm ~ 6–7) were collected and lysed in 200 μl
of Laemmli buffer, and 15 μl of the lysate was then employed
in SDS-PAGE.
Purification of chimeric HBc VLP and HBc VLPs
Overnight E. coli bacterial culture at 18 °C (transformed E. coli
cells) was centrifuged at 5000 rpm for 20 min at 4 °C to collect
the bacterial cells. After this, the cells were washed three times
with PBS (pH 7) to remove any proteolytic agent, and then
resuspended in lysis buffer (50 mM Tris-HCl, pH 8, 150 mM
NaCl, 5 mMDTT, 0.1% Triton X-100, 10mMEDTA, 0.5 mM
urea, 1 mg/ml lysozyme, 1× protease inhibitor cocktail
(Roche)). Purification of protein was performed by incubation
of the cells (4 g) in 16 ml of lysis buffer on ice for 30 min, and
then the cells were lysed six times by ultrasonication with 40%
amplitude with 20 s on and 50 s off on ice. The lysate became
transparent by centrifugation at 12,000 rpm for 30 min at 4 °C.
Solid ammonium sulfate was then added to the supernatant
until it reached 35% saturation and incubated overnight at 4
°C. The next day, suspension was centrifuged at 10,000 rpm
for 30 min at 4 °C. The precipitated protein was dissolved in
20 mM Tris-Hcl buffer pH 8, containing 150 mM NaCl,
10 mM EDTA, 0.1% Triton X-100 (Sigma-Aldrich,
Germany), and 1× protease inhibitor cocktail (Sigma-Aldrich,
Germany). It was then heated at 55 °C for 30 min, and contam-
inating proteins were removed by centrifugation at 9000 rpm
for 15 min at 4 °C. Then VLPs were further purified by con-
ventional anion exchange chromatography. To this end, the
supernatant was first dialyzed against binding buffer (20 mM
Tris-Hcl, pH 8, 150 mMNaCl, 0.1% Triton X-100, 1× protease
inhibitor cocktail, and 0.5 M urea (Merck, UK). Proteins were
fractioned with the AKTA Prime Plus FPLC system (GE
Healthcare) equipped with a column packed with
diethylaminoethyl (DEAE) column (GE Healthcare,
Germany) as the anion exchange matrix. Proteins were eluted
by a linear gradient mixture of binding buffer (20 mMTris-HCl
pH 8.6) supplemented with 1 M NaCl solution as described
elsewhere (Mohamadi et al. 2016) and VLPs were precipitated
by adding ammonium sulfate to reach a final saturation of 50%
and then the precipitated VLPs were dissolve and dialyzed by a
working buffer (50 mM Tris-Hcl, pH 8 and 150 mM NaCl,
2 mM DTT, 1× protease inhibitor cocktail).
HBc VLP formation analysis
Native agarose gel electrophoresis (NAGE) as a simple meth-
od was used to evaluate VLP formation through the presence
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of the same band of protein and nucleic acids on native aga-
rose gel electrophoresis (NAGE). For NAGE, 0.7% UltraPure
agarose (Invitrogen, USA) in TAE buffer (40 mM Tris,
20 mM acetic acid, 1 mM EDTA) was used. The purified
VLPs (1.5 mg/ml) were loaded on a 0.7% agarose gel, and
electrophoresis was performed for 40min at 100 V. Following
the staining of the gel with EtBr solution (TAE buffer + 1
μg/ml EtBr), the gel was stained with Coomassie Blue
G-250 (60 μg/ml of Coomassie Blue G-250 in 10% acetic
acid). After early detection of VLP formation by NAGE, elec-
tron microscopy was employed in order to direct observation
of VLP particles. For this purpose, VLP containing Tris buffer
was adsorbed onto carbon formvar–coated copper grids and
negatively stained with a 1% uranyl acetate aqueous solution;
then grids were evaluated with a ZEISS EM900 transmission
electron microscope.
Synthesis and characterization of C-terminal half of
Che a 3 peptide (C. Che a 3 peptide)
The C-terminal half of Che a 3 (C. Che a 3 peptide) was
synthesized using a solid-phase synthesis method using
N-(9-fluorenyl) methoxycarbonyl (Fmoc) chemistry
(Pepmic, Suzhou, China). These peptides were then purified
by RP-HPLC using SHIMADZU Inertsil ODS-SP (4.6 ×
250 mm × 5 μm) column, which was eluted by a 0–100%
H2O/acetonitrile gradient containing 0.1% trifluoroacetic acid
(TFA) for 30 min. Homogeneity of the peptide was assayed
by analytical high-performance liquid chromatography using
Inertsil ODS-SP (4.6 × 250 mm × 5 μm) column that demon-
strated a 90% purity. The atomic mass of the purified peptides
was determined by mass spectrometry (MS).
Allergic patients
Sera from 9 males and 6 females (with mean ages 30.13 years
old) with a clinical history of respiratory allergy, positive skin
prick test (SPT) for C. album, and positive result with com-
mercial enzyme allergosorbent test (EAST; Dr. Fuke,
Germany) were collected. Afterward, the sera were investigat-
ed for the presence of Che a 3–specific IgE by recombinant
Che a 3 (rChe a 3)-based ELISA (Table S1) to choose rChe a
3-sensitized patients’ sera. The rChe a 3 protein is the recom-
binant form of full-length rChe a 3 protein expressed in E. coli
B strain (DE3) that was kindly gifted by Dr. A. Varasteh (Bu-
Ali Research Center, Mashhad, Iran), and a full description of
its production has been described elsewhere (Nouri et al.
2012). For the negative control, sera were collected from sev-
en healthy individuals with no history of allergy and also with
negative SPT for the commercial crude extract of C. album.
ELISA assay for IgE reactivity of chimeric HBc VLP,
rChe a 3, and C. Che a 3 peptide
IgE reactivity of rChe a 3 protein, C. Che a 3 peptide, chimeric
HBC VLP, and HBc VLP were examined with rChe a 3–
sensitized patients’ sera by ELISA method. For ELISA, plate
wells were coated with 10 μg/ml of rChe a 3, C. Che a 3,
Fig. 1 Schematic representation of construct plasmid, production, and
confirmation of VLP formation. a Map of HBc and chimeric HBc
(Chi.HBc) plasmids, Che a 3 was inserted in Eco R1/Nhe1 enzyme
cleavage sites on the major insertion region (MIR) on the HBcAg
protein. b Analysis of the expression and purity of recombinant proteins
by SDS-PAGE. Line A: total cell lysates of chimeric HBc-expressing
BL-21 E.coli bacteria; line B: chimeric HBc VLPs (26.62 kDa) were
purified by anion exchange chromatography; line C: total cell lysates of
HBc-expressing BL-21 E. coli bacteria; line D: HBc VLPs (20.9 kDa)
were purified by anion exchange chromatography; and line M: low
molecular weight protein marker (LMWM, kDa). c NAGE analysis of
purified chimeric HBc and HBc VLPs, NAGE analysis of purified HBc,
and chimeric HBc VLP by coomassie (left) and ethidium bromide (right)
staining. Lines A and B represent chimeric HBc VLPs and HBc VLP,
respectively. d Representation of protein structure of HBc (left), chimeric
HBc (right). e Electron microscopy confirmed VLP formation for HBc
and chimeric HBc VLPs
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chimeric HBc VLP, or HBc VLP diluted in 0.2 M bicarbonate
buffer pH 9.0. After overnight incubation at 4 °C, the wells were
washed three timeswith 1× phosphate-buffered saline and 0.05%
Tween-20 (PBS-T) and then blocked with 1% bovine serum
albumin (BSA). The blockedwells werewashed three timeswith
PBS-T, exposed to either sera from rChe a 3–sensitized patients
(1:5 diluted patient sera) or to 1:5-diluted sera from healthy indi-
viduals (n: 7), and incubated for 2 h at 37 °C. Afterward, the
wells were washed three times PBS-T and exposed to 1:2000-
diluted biotin-labeled anti-human IgE (Abcam, USA). Again
after three times washing with PBS-T, the wells were incubated
for 1 h with 1:30,000-diluted horseradish peroxidase (HRP)–
conjugated streptavidin (Sigma, MO, USA). After the addition
of TMB/H2O2 chromogen/substrate (Sigma, MO, USA), the
plates were incubated in the dark for 15 min. The reaction was
stopped by adding 100 μl of 2 N H2SO4 solutions. Finally, the
optical density (OD) of the wells was measured at two wave-
lengths of 450 and 630 nm to remove optical interference and
background signals from unwanted reactions.
Basophil activation assays
Basophil activation test was performed as previously de-
scribed (Sanz et al. 2001). To this end, 15 ml of heparinized
peripheral whole blood sample was obtained from five pa-
tients with positive skin prick test (SPT) for C. album.
Heparinized blood samples (from rChe 3–sensitized patients)
were then centrifuged (500 g at 4 °C) for 10 min and buffy
coat was collected and centrifuged (500 g at 4 °C) for 10 min.
The supernatant was removed, and the cell pellet was dis-
solved in stimulation buffer (100 μl) contained 2 ng/ml of
interleukin 3 (IL-3) (20 mM HEPES, 133 mM NaCl, 5 mM
KCl, 7 mM CaCl2, 3.5 mM MgCl2, 1 mg/ml BSA, pH 7.4).
Then various dilutions (100 μl) of rChe a 3, C. Che a 3, or
chimeric HBc VLPs were added to the suspension and incu-
bated at 37 °C for 20 min. Anti-IgE mAb (1 μg/ml)
(Immunotech, Marseille, France) and PBS (negative control)
were used as positive and negative controls, respectively.
Afterward, red blood cells (RBCs) were lysed with RBC lysis
buffer (Abcam), centrifuged at 500 g for 10 min, and washed
twice with a wash buffer (PBS containing 2% FCS). The cells
were dissolved in a wash buffer and incubated with PE anti-
human CD63 and FITC anti-human CD193 (CCR3) antibod-
ies (Biolegend, London, UK) at 25 °C for 30 min. The stained
cells were evaluated using fluorescence-activated cell sorting
(FACS), and the data were analyzed using the FlowJo soft-
ware (version 7.6.1).
Immunization of mice and assessment of rChe a 3–
specific IgG response
Female Balb/c mice (6–8 weeks of age) were purchased from
Animal Laboratory, Pasture Institute of Iran. The animals
were kept at a constant temperature (25 °C) and were fed with
customary laboratory food and water. All animal procedures
were conducted according to the ethics committee of Bushehr
University of Medical Sciences to the “Guide for the Care and
Use of Laboratory Animals” from the US National Institutes
of Health (Care IoLARCo, Animals UoL, Resources
NIoHDoR 1985). Seven groups of mice (five mice/group)
were subcutaneously immunized on days 0, 14, and 21 with
rChe a 3 protein (25 μg) or C. Che a 3 peptide (25 μg) that is
mixed with either an equal volume (50 μl) of alum (2% w/v)
or HBc VLP (10 μg), chimeric HBCVLPs (10 μg), HBc VLP
(10 μg), and PBS. The sera of the mice were evaluated on
days 0, 14, 21, and 28 after the first immunization in terms of
antibody response. For the measurement of rChe a 3–specific
IgG response in the sera of the mice, the wells were coated
with 10 μg/ml of rChe a 3 and incubated with a 10-fold serial
dilution of the sera of the mice (non-immunized or immunized
sera). After the washing steps, the wells were developed with
1/1000-diluted goat anti-mouse IgG-HRP (Biolegend, UK)
for 2 h at room temperature (RT). Then, the rChe a 3–
specific IgG response in immunized mice was calculated with
TMB/H2O2 chromogen/substrate (Sigma, MO, USA) at OD
450/630 nm. The endpoint titer for each sample was deter-
mined and used to compare IgG levels between mice groups.
For this purpose, cutoff titers were determined for each serum
dilution by calculating the absorbance (mean + 3 standard
deviat ion) obtained from each serum dilution of
preimmunized mouse. The titer endpoint for each sample
was expressed as reciprocal of the highest 10-fold dilution that
had an absorbance greater than the corresponding cutoff
values obtained from preimmunized mice sera. ELISA was
performed in triplicate for all samples.
Evaluation of rChe a 3–specific IgE response in the
sera of immunized mice
Sera from immunized mice of previous experiments were in-
vestigated to determine the rChe a 3–specific IgE response. To
this end, the wells coated with rChe a 3 (10 μg/ml) were
blocked with 1% BSA and incubated with a 5-fold dilution
of mice sera (immunized sera) for 2 h at 37 °C. The wells were
washed three times with PBS-T and developed with 1/500-
diluted goat anti-mouse IgE-HRP (Thermo Scientific,
Waltham, MA, USA) for 2 h at RT. Then, the rChe a 3–
specific IgE response in immunized mice sera was determined
by adding TMB/H2O2 chromogen/substrate at 450/630 as de-
scribed above.
Inhibition of allergic patients’ IgE binding to rChe a 3
by immunized mice sera
Competitive inhibition ELISA assay was used to assess
blocking allergic patients’ IgE binding to rChe a 3 by sera
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from immunized mice. For ELISA inhibition, ELISA wells
were coated with 10 μg/ml of rChe a 3, and after blocking
with 1% BSA, these coated wells were incubated with 10-fold
serial dilution of mice sera from immunized mice or
preimmunized mice (1:100 v/v), and after the washing step,
wells were incubated with pool sera from rChe a 3–sensitized
patients (n: 10) or non-sensitized individuals (n: 7, 1:5 v/v). In
the next step, wells were developed with 1:2000-diluted
biotin-labeled anti-humans IgE (Abcam, USA) and then with
1:30000-diluted HRP-conjugated streptavidin (Sigma, MO,
USA) for 1 h at RT. The inhibitory effect of sera from immu-
nized mice on allergic patients’ IgE binding to rChe a 3 was
calculated by the following formula:
(OD of sample without inhibitor-OD of sample with
inhibitor/OD of sample without inhibitor) × 100.
Determination of IgG subclasses and cytokine
responses in immunized mice
The titers of two subclasses of antibodies (IgG1/IgG2a) were
examined in mice sera by ELISA. To this end, plates were
coated with rChe a 3 (10 μg/ml) diluted in 0.2 M bicarbonate
buffer, pH 9.0, and left overnight at 4 °C. The coated wells
were washed three times with PBS-T and blocked with 1%
BSA by incubation at 37 °C for 2 h. The blocked wells were
then washed three times with PBS-T and incubated with
100 μl of 1:100-diluted mice sera. After washing steps, the
wells were incubated with 100 μl of diluted biotin-labeled
anti-mice IgG (Mab Tech, Stockholm, Sweden), including
1:1000 anti-IgG1 or 1:250 anti-IgG2a for 2 h at RT. The wells
were then washed again with PBS-T and incubated for 1 h
with 1:3000-diluted HRP-conjugated streptavidin. Non-
binding HRP-conjugated streptavidin was removed by wash-
ing; TMB/H2O2 chromogen/substrate (Sigma, MO, USA)
was added to the plates and incubated in the dark for 15
min. The reaction was stopped by the addition of 100 μl of
2 N H2SO4 solutions. Finally, the optical density (OD) of the
wells was measured at 450 nm. Sera, secondary antibodies,
and HRP-conjugated streptavidin were diluted in 1% BSA.
For cytokine response assay (IFN-γ), mouse splenocytes
were isolated on day 42 and were converted to single-cell sus-
pension in RPMI 1640 by passing through mesh with pore size
70 μm under aseptic conditions. Red blood cells were removed
by osmotic shock, and the cells were washed with RPMI 1640
and resuspended in medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS) from cattle/bovine
(Gibco, Fisher Scientific, UK) 100 IU/ml penicillin and 100
μg/ml streptomycin. Mouse splenocytes were stimulated with
rChe a 3 (5 μg/ml), HBc VLP (5 μg/ml), or phytohemagglutinin
(PHA, 5 μg/ml) as positive control (5 μg/ml). In addition, the
wells containing mouse splenocytes were incubated with PBS as
unstimulated control. After 48 h, the supernatant of cell cultures
was removed, and the cytokine level was examined with mouse
IFN-γ ELISA set (Mouse IFN-γ ELISA MAX™ Standard)
according to the manufacturer’s instructions. All materials for
culture were purchased from Gibco, UK.
Statistical analysis
The obtained data were analyzed and compared using one-
way ANOVA or student’s unpaired t test. A p value of less
than 0.05 was considered statistically significant. The
GraphPad Prism 6 software was used to depict the charts.
Results
Construction, expression, and purification of chimeric
HBc VLPs and HBc VLPs
In the present study, we constructed a hybrid containingChe a 3–
derived peptides (C. Che a 3) fused to HBc protein in order to
compare immune responses induced by allergen-derived peptide
or full-length allergen either mixed with HBc VLPs or allergen-
derived peptide linked to HBc VLPs. For this purpose, the
encoding gene for the C-terminal half of Che a 3 with EcoR1/
Nhe1 cleavage site at both ends and CoHBc plasmid were
digested with EcoR1/Nhe1 enzymes, and after the ligation of
C. Che a 3 into the MIR site of HBc-coding sequence, vaccine
construct (chimeric HBc) was created and termed chimeric HBc
VLPs (Fig. 1a).
The recombinant protein chimeric HBc VLPs and HBc VLPs
were successfully expressed in E. coli BL21 (DE3). After the
preliminary confirmation of VLP formation in cell lysate by
NAGE, VLPswere precipitated by ammonium sulfate from clar-
ified supernatant, and for further purification, the suspension
containing VLPs undergone anion exchange chromatography
(Fig. 1b). To estimate the concentration of purified VLP mate-
rials, fractions containing VLPs were pooled and the Bradford
result indicated approximately a yield of 6 and 8mg/L culture for
chimeric HBc VLPs and HBc VLPs.
Characterization of VLPs
The observation of a corresponding band in Coomassie
and ethidium bromide staining of NAGE indicated the
formation of VLP and encapsulation of nucleic acids in
VLPs. Homogeneity analysis of HBc- and chimeric HBc
VLPs by NAGE gel showed that some chimeric HBc
particles do not run onto the NAGE under electropho-
resis and stay in the wells of the gel; this can be due to
the aggregation or undesirable disassembly (Fig. 1c).
For direct observation and confirmation of VLP forma-
tion, a suspension containing VLPs was evaluated by
negative-staining transmission electron microscopy, and
VLP formation by self-assembling of monomeric
82 Appl Microbiol Biotechnol (2021) 105:77–91
chimeric HBc protein into chimeric HBc VLPs was
demonstrated (Fig. 1e).
C-terminal half of Che a 3 peptide (C. Che a 3) and
chimeric HBc VLPs showed very low IgE reactivity
compared to rChe a 3
The IgE reactivities of C. Che a 3 peptide, chimeric HBc
VLPs, and rChe a 3 were evaluated by ELISA. ELISA data
revealed a significant reduction for IgE reactivity of C. Che a 3
peptide and chimeric HBc VLPs (13.00- and 11.14-fold, re-
spectively) compared with rChe a 3, in which mean ODs for
IgE reactivity of rChe a 3 was estimated as 0.78 ± 0.15, while
for C. Che a 3 peptide and chimeric HBc VLPs were 0.06 ±
0.01 and 0.07 ± 0.01, respectively. No significant difference
was observed for IgE reactivity of C. Che a 3 peptide or
chimeric HBc VLPs in the sera from rChe a 3–sensitized
patients (Fig. 2).
C-terminal half of Che a 3 peptide (C. Che a 3) and
chimeric HBc VLPs are almost unable to upregulate
CD63 expression
A basophil activation test was used to determine the allergenic
properties of rChe a 3, C. Che a 3, and chimeric HBc VLPs
using PBMCs from rChe a 3–sensitized patients. C. Che a 3
and chimeric HBcVLPs failed to upregulate CD63 expression
(as the specific basophil activation marker), even at high con-
centrations, while rChe a 3 strongly triggers CD63 expression
in a dose-dependent manner (Fig. 3).
Chimeric HBc VLPs induce a rapid and robust IgG
response
The antibody response in immunized sera was assessed by
indirect ELISA method. Chimeric HBc VLPs induced robust
and fast rChe a 3–specific antibody response so that only 2
weeks after the first immunization, a high titer of specific IgG
antibody was observed in comparison to those induced by
other antigens. Furthermore, 4 weeks after the first immuniza-
tion, rChe a 3–specific IgG antibody in mice immunized with
chimeric HBc VLPs was significantly higher than that in mice
immunized with the other antigens. No significant difference
was observed in the antibody titer when allergen or allergen-
derived peptide mixed with alum or HBc VLPs. The mice
immunized with HBc VLPs resembled mice immunized with
PBS were not able to produce rChe a 3–specific IgG (Fig. 4).
RChe a 3mixed with alum induced the highest level of
rChe a 3–specific IgE antibody in mice
The ability of antigens to trigger rChe a 3–specific IgE anti-
body was evaluated in mice after the immunization. As shown
in Fig. 5, rChe a 3 or C. Che a 3 mixed with alum induced a
higher level of rChe a 3–specific IgE antibody in comparison
mixing with HBc VLP. Furthermore, full-length allergen
(rChe a 3), particularly in combination with alum, produced
the highest level of rChe a 3–specific IgE antibody compared
to the other antigens. Interestingly, mice immunized with C.
Che a 3 (when mixed with HBc VLP) or chimeric HBc VLPs
produced the lowest level of rChe a 3–specific IgE antibody.
Moreover, chimeric HBc VLPs produced less level of rChe a
3–specific IgE antibody compared to that produced by C. Che
a 3 mixed with alum.
Chimeric HBc VLPs produced the highest level of rChe
a 3–specific blocking IgG antibodies
ELISA findings revealed that in comparison to the other
antigens, chimeric HBc VLPs produced IgG antibodies
in mice which were able to inhibit the binding of aller-
gic patients’ IgE to rChe a 3 even in the high mouse
antisera dilution, so that at 1:102- to 1:106-fold dilution
of sera, only a slight change was observed in blocking
Fig. 2 C. Che a 3, chimeric HBc
VLP showed a highly reduced
IgE reactivity. IgE reactivity of
rChe a 3, C. Che a 3, and chimeric
HBc VLPs were determined by
ELISA. Chart represents the
comparison of IgE reactivity of
rChe a 3, C. Che a 3, chimeric
HBc VLP, and HBc VLP by
ELISA in sera from sensitized
patients (n: 15) and healthy
individuals (n: 7). p value less
than 0.05 was regarded as
statistically significant. Symbol
signs: *, p ≤ 0.05; **, p ≤ 0.01;
***, p ≤ 0.001; n.s: not significant
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IgG titer produced by chimeric HBc VLPs. The full
length of allergen (rChe a 3), mixed with either alum
or HBc VLPs, produced a higher titer of blocking IgG
than the C-terminal half of allergen (C. Che a 3).
Likewise, there was no significant difference between
the level of blocking IgG induced by C. Che a 3 pep-
tide when applied in combination with alum or HBc
VLPs (Fig. 6).
The ratio of IgG1/IgG2a antibodies reduced in mice
immunized with chimeric HBc VLPs
Reduction in IgG1/IgG2a ratio in mice is considered the de-
viation of the immune system towards a Th1 response. In
comparison to mice immunized with rChe a 3 or C. Che a 3
peptide (mixed with alum or HBc VLP), a reduction in
IgG1/IgG2a ratio was observed in sera from mice immunized
Fig. 3 Chimeric HBc VLPs fail to activate human basophil cells. Whole
blood cells from rChe a 3–sensitized patients (n: 5) were incubated with
rChe a 3, C. Che a 3, chimeric HBc VLPs, anti-IgE, or PBS. The
upregulation of CD63 (basophil activation marker) was assayed on
CCR3-gated cells (basophil) using flow cytometery. a The flow chart
represents one experiment out of five for each protein that showed the
percentage of CCR3 (CD193), CD63 double-positive cell (activated
basophil). b The percentage of activated basophil (CCR3, CD63
double-positive cell subset) induced by each protein was calculated and
expressed as mean ± SD. The percentage of CCR3, CD63 double-
positive cells of each protein compared with that of PBS-treated whole
blood cells. Symbol meaning: *, p value ≤ 0.05 that was calculated by
multiple t test and one-way ANOVA
Fig. 4 Chimeric VLPs produce
the highest level of rChe a 3–
specific IgG in mice. Comparison
of rChe a 3–specific IgG Ab titer
in mice immunized (five mice per
group) with rChe a 3, C. Che a 3,
chimeric HBc VLPs, HBc VLPs,
or PBS on days 14, 21, and 42.
Symbol meaning: *, p value ≤
0.05 that was calculated by
multiple t test and one-way
ANOVA
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with chimeric HBc VLPs. This Th1-biased immune response
in mice immunized with chimeric HBcVLPs can be due to the
presence of encapsidated nucleic acids in chimeric HBcVLPs.
RChe a 3 or C. Che a 3 peptide (mixed with alum or HBc
VLPs) induced antibody response more toward IgG1 com-
pared to IgG2a, suggesting that rChe a 3 or C. Che a 3 might
induce a Th2-skewed immune response (Fig. 7).
Similar to antibody response, in vitro cytokine assay con-
firmed that only chimeric HBc VLPs could induce allergen-
specific Th1 immune response. Splenocytes frommice immu-
nized with rChe a 3, C. Che a3 peptide, chimeric HBc VLPs,
or HBc VLPs were stimulated in vitro using rChe a 3 or HBc
VLPs. Splenocytes from mice receiving chimeric HBc VLPs
produced a higher level of IFN-γ when stimulated with either
HBc VLPs or rChe a 3, while splenocytes from mice that had
received either HBc VLPs alone or in combination with aller-
gen were capable of producing IFN-γ, only when their
splenocytes were stimulated with HBc VLPs (no with rChe
a 3 ) (Fig. 8).
Discussion
Virus-like particles induce immune responses via several
ways that make them very attractive for use in allergy vaccines
(Klimek et al. 2018; Li et al. 2011; Xu et al. 2014). The desired
features of VLPs that are suitable for application in patients
with allergic rhinitis include (i) efficient draining into the
lymph nodes owing to these nanoparticle structures (30–100
nm) can induce a robust humoral immune response and (ii)
Fig. 6 Anti-chimeric HBc VLP IgG antibody produces the highest level
of blocking IgG that inhibits allergic patients’ IgE binding to rChe a 3. a
The chart represents mean absorbance value for allergic patients’ IgE
reactivity to rChe a 3 that has been pre-incubated with various dilutions
of mice sera. RChe a 3 was first incubated with various dilution sera from
immunized mice within each group (five mice/group), and then probed
with pool sera from allergic patients’ sera (n: 10). Mean ± SD of each
group was compared with HBc VLP group by one-way ANOVA. b
Percent inhibition of allergic patients’ IgE binding to rChe a 3 by sera
forms immunized mice in two antiserum dilution. p values less than 0.05
were regarded as statistically significant that were calculated bymultiple t
test and one-way ANOVA
Fig. 5 Chimeric VLPs and C. Che a 3 produce the lowest level of rChe a
3–specific IgE in mice. Forty-two days after first immunization, the level
of rChe a 3–specific IgE antibody was evaluated in the sera of mice
immunized (five mice per group) with rChe a 3, C. Che a 3, chimeric
HBc VLPs, or HBc VLPs. The data represents the level of rChe a 3–
specific IgE antibody (mean ± SD) in each group. p values less than 0.05
were regarded as statistically significant.
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adjuvant properties of VLPs that induce a polarization toward
Th-1 response (Klimek et al. 2018) that is known as a favor-
able response for allergy treatment (Kündig et al. 2015). It
demonstrated that VLP is a safe and well-tolerated vaccine
that is currently used as prophylactic vaccine against hepatitis
B virus and human papillomavirus. Similarly, the application
of VLPs alone or simply mixed with HDM extract in clinical
trial studies induces a positive effect on symptoms of allergic
rhinitis and asthma, owing to the adjuvant effect of VLP-
induced Th1 response (Kündig et al. 2015). Therefore, HBc
VLP can be used as safe, non-allergenic therapeutic treatment
platform using allergens and allergen derivatives to induce
protective immune responses against allergen in allergy-
related diseases (Klimek et al. 2018; Kündig et al. 2015;
Siskind et al. 1966).
Studies have previously established that the hypoallergenicity
and immunogenicity are two important issues for immunothera-
py (Himly et al. 2012; Kulis et al. 2012); hence, in this study, we
designed, generated, and characterized the hypoallergenic HBc
VLPs presenting allergen-derived peptide. Genetic engineering
was employed to insert C-terminal half of Che a 3 (C. Che a 3)
into the MIR of HBc antigen and displayed C. Che a 3 in a
repetitive fashion on the surface of HBc VLPs. Similar to HBc
protein, chimeric HBc VLPs retain the self-assembly property
andVLP formationwhen expressed inE. coli expression system,
so prokaryotic expression systems can be used for chimeric HBc
VLP-producing systems. Severe allergic reactions, including
anaphylaxis, which is life-threatening, are important concerns
of allergen-specific immunotherapy that may limit wide clinical
use of AIT (Burks et al. 2013; Valenta 2002). In this respect,
ELISA findings demonstrated a strong reduction in the IgE re-
activity of C. Che a 3 and chimeric HBc VLPs compared with
rChe a 3 allergen. The reduced IgE reactivity of C. Che a 3 may
be due to the disruption of three-dimensional structure of Che a 3,
because previous studies demonstrated that the IgE reactivity of
two EF-hand calcium-binding allergens (i.e., parvalbumin and
Fig. 7 Chimeric HBc VLPs induce an antibody subclass response favor
Th1 response. a The average of antibody subclass titer was measured by
ELISA in eight groups (5 mice in each group); chimeric HBc VLPs
produced a higher level of IgG 2a relative to other antigens. b Char
represent mean ± SD (n: 5) of rChe a 3–specific IgG1/IgG2a ratio in
each group. Mean ± SD (IgG1/IgG2a ratio) of mice immunized with
chimeric HBc VLPs was compared with other groups using multiple t
tests, one per row. p values less than 0.05 were regarded as statistically
significant that were calculated by multiple t test and one-way ANOVA
Fig. 8 Utilization of VLPs as platform induces a robust IFN-g response.
Splenocytes of mice immunized with HBc VLPs alone or HBc VLP
mixed with allergen induced a high level of IFN-g when only
stimulated with HBc VLPs (no with rChe a 3), while splenocytes of
mice immunized with chimeric HBc VLPs produced high IFN-g when
stimulated with either HBc VLPs or rChe a 3. p values less than 0.05 were
regarded as statistically significant that were calculated by multiple t test
and one-way ANOVA
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polcalcins) depends on their three-dimensional structure
(Mohammadi et al. 2017; Swoboda et al. 2007; Westritschnig
et al. 2004). These studies indicated that a disruption or alteration
in the three-dimensional structures of twoEF-hand calcium-bind-
ing allergens, by mutations in the calcium-binding site or frag-
mentation, led to the generation of a hypoallergenic variant
(Mohammadi et al. 2017; Swoboda et al. 2007; Westritschnig
et al. 2004). Consistent with these results, the basophil activation
test demonstrated that chimeric HBcVLP andC. Che a 3 peptide
at same the level exhibited very low basophil degranulation-
triggering ability compared to that triggered by rChe a 3. In
agreement with this result, it has been demonstrated that repeti-
tive displaying of allergen on the surface of VLPs, by chemical
conjugation, led to loss of its basophil degranulation-triggering
ability (Engeroff et al. 2018).
Inducing a robust and long-lasting antibody response
(humoral immunity) and T helper cell (cellular immunity)
is crucial to a successful immunotherapy (Klimek et al.
2013; Klimek et al. 2011). Evaluation of quantity and qual-
ity of the induced antibody response in mice revealed that a
physical association between the allergen derivative (C.
Che a3) and HBc VLPs (chimeric HBc VLP) is required
for producing allergen-specific IgG2a antibody and a Th1
response. Thus, a single immunization with chimeric HBc
VLPs induced a strong IgG response against rChe a 3 in
comparison to those induced by allergen or its derivatives
mixed with either HBc VLPs or alum. The reduced ratio of
allergen-specific IgG1/IgG2a in mice immunized with chi-
meric HBc VLPs compared with that of immunized with
rChe a 3 mixed with VLPs confirmed the induction of an
allergen-specific Th1 response. This finding suggests that
when allergen-derived peptide is physically linked to HBc
VLPs, allergen-specific B cell simultaneously takes up both
allergen-derived peptide and HBc VLPs. This may be the
reason for the strong antibody induced by chimeric HBc
VLPs compared to when the allergen is simply mixed with
HBc VLPs that describe hapten-carrier and adjuvant effect
of VLPs on antigen-presenting cells (i.e. ,B cells) (Siskind
et al. 1966). In agreement with this finding, Gomes et al.
demonstrated that physical association of antigen, VLPs
and adjuvant are very crucial for B cell response (Gomes
et al. 2017). Furthermore, the presentation of allergen de-
rivatives on the surface of VLPs in a repetitive fashion en-
hances cross-linking of BCR those results in inducing a
strong humoral immune response (Gomes et al. 2017).
Schmitz et al. created high immunogenic and protective
treatment against cat allergy by chemical coupling of major
cat allergen Fel d1 to bacteriophage Qβ-derived virus-like
particles which induced a protective and robust IgG re-
sponse after a few injections. This ability is due to the in-
corporation of RNA into VLP during production of Qβ-
derived VLPs in E. coli (Schmitz et al. 2009). However,
coupling of antigen to VLPs by chemical coupling often
leads to a lower density of the target epitope on the surface
of VLP, as also, chemical coupling of complex antigens
with several reactive sites to VLPs may complicate the cor-
rect coupling of antigen to VLPswhich is crucial for optimal
display of the epitope (Pattenden et al. 2005; Smith et al.
2013). It seems that the antigen displayed on VLP by genet-
ic fusion may be an efficient strategy to overcome draw-
backs of chemical coupling of antigen to VLPs. In this
way, Arora et al. displayed envelope domain III (EDIII)
from dengue viruses on the surface of HBc VLP and dem-
onstrated that this chimeric particle was very immunogenic
and induced high-titer anti-EDIII-2 protective IgG response
(Arora et al. 2012).
Deviation of the immune response toward Th2 response
is observed in allergic diseases. The purpose of allergy im-
munotherapy is to induce energy in allergen-specific Th2 or
skew the immune response toward Th1 response (Smarr
et al. 2013). Splenocytes obtained from mice were stimulat-
ed in vitro with allergen or HBc antigen to determine
antigen-specific cytokine response. Splenocytes from mice
immunized with either HBc VLPs alone (group HBc VLPs),
chimeric HBc VLPs, or HBc VLPs mixed with allergen or
its derivatives (groups: rChe a 3 + VLPs, C. Che a 3 + VLPs)
produced high level of IFN-γ in response to in vitro stimu-
lation with HBc antigen compared with those immunized
with rChe a 3 or C. Che a3 mixed with alum (groups: rChe a
3 + alum, C. Che a 3 + alum) or PBS group. However, in
splenocytes of mice stimulated with rChe 3, only those mice
immunized with chimeric HBc VLPs produced significant
secretion of IFN-γ. Production of IFN-γ by splenocytes
from mice immunized with chimeric HBc VLPs may be
due to the existence of elevated allergen-specific CD4+ cells
(Th1) that might have been induced by chimeric HBc VLPs
in mice after immunization (Ebert and Jabri 2008). The
encapsidated nucleic acids (RNA, DNA) into chimeric
HBc VLPs during self-assembly of the coated proteins in
E. coli act as agonists of TLR3/7/9 (Kanzler et al. 2007) and
induce Th1-skewed immune response. Klimek et al. evalu-
ated the efficiency of allergen-free QB-VLP vaccine for
immunotherapy of patients with allergy to mites and dem-
onstrated that VLPs containing TLR9 agonist reduced aller-
gy symptom in allergic patients after the administration
(Klimek et al. 2011). Sominskaya et al. indicated that the
truncated HBc variant, lacking the nucleic acid–binding do-
mains, can induce a dominant Th2 response compared to the
full length of HBc VLP that contains encapsidated RNA
(Sominskaya et al. 2013).
Although chimeric HBc VLP induces the highest level of
rChe a 3–related IgG antibody, the lower potency of chime-
ric HBc VLP to produce IgE antibody in mice after immu-
nization, even compared to C. Che a 3 mixed with alum,
suggests that the chimeric HBc VLP can skew immune re-
sponse toward Th1 response, resulting in a reduction of
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Th2-mediated IgE production. In contrast, the combination
of allergen with alum, compared with HBc VLP, leads to the
increase of rChe a 3–related IgE antibody, which may be
due to Th2 response mediated by alum (Terhune and Deth
2018). These results suggest that HBc VLP is superior to
alum in driving an immune response against allergic disease
due to inducing a Th1 response. Prior studies demonstrated
that aluminum adjuvants contribute to the ongoing develop-
ment of the risk factors of allergies (Johnson-Weaver et al.
2018; Terhune and Deth 2018).
Taken together, antibody and cytokine assays revealed that
the application of VLPs in combination with allergen (either
linked or simply mixed) induced HBc VLP-specific Th1-
skewed immune response that had positive effect on symp-
toms of allergic rhinitis (Kündig et al. 2015). However, chi-
meric HBc VLPs, in contrast to other antigen formulations,
not only induce an allergen-specific Th1-biased immune re-
sponse but also produce high allergen-specific antibody re-
sponse (especially IgG2a antibody) that can block an allergic
patient’s IgE binding to rChe a 3 and subsequently inhibit
allergen-induced systemic basophil degranulation (Schmitz
et al. 2009). Another therapeutic effect of allergen-specific
IgG antibody includes the inhibition of IgE-mediated allergen
exposure by dendritic cells and reduction of allergen-specific
Th2 cells and IgE response (Sharquie et al. 2013; Valenta et al.
2009).
The main drawback of previous strategies to reduce al-
lergenicity and create hypoallergenic forms of allergens
(mutation, deletion, or inversion in the deduced amino acid
sequence of allergens) is to disrupt and delete Th cell epi-
topes required for induction of an immune response. In oth-
er words, these epitopes determine immunogenicity
(Alexander et al. 2005; Campana et al. 2014; Oldfield
et al. 2001); therefore, the conjugation or fusion of allergen
derivatives to a highly immunogenic carrier and rich in Th
cell epitopes like HBc VLP can overcome this problem. In
some studies, CpG motifs were used as adjuvant (Salem
2014; Senti et al. 2009) to increase the Th1 response against
an allergen, but it has been demonstrated that free CpGs can
induce splenomegaly after immunization compared to pack-
aged CpG (Storni et al. 2004). For the first time, we studied
the efficiency of VLP from hepatitis B core antigen (HBc)
as a vaccine platform for the presentation of hypoallergenic
allergen-derived peptides to the immune system. In this
study, we specifically wanted to compare the allergen-
specific immune response of mice receiving chimeric HBc
VLP or allergen mixed with either HBc VLP or alum. As the
mouse responses to HBc VLP are highly characterized, we
included different combinations or individual treatments. It
is important to note that the combination of HBc VLP +
alum was not included in our study and may reduce the
signal to background ratio of the immunoglobulin measure-
ments; it does not affect the differences seen between the
treatment groups. We believe that the treatment with chime-
ric HBc VLP has advantages, including the production of
high level of allergen-specific IgG antibody and also induc-
tion of allergen-specific Th1 response when allergen simply
mixed with HBc VLPs or alum. Further research is needed
to evaluate the protective effects induced by chimeric HBc
VLP in allergic mice models, and also determine allergenic-
ity of chimeric HBc VLP in vivo and in vitro by a skin prick
test and basophil activation test (BAT), respectively. Given
that tradiational allergy immunotherapy has several draw-
backs such as several shots over a long time due to the low
immunogenicity, risk of anaphylaxis, and sometimes the
lack of a curative effect, hence, we described strategies that
removed drawbacks related to allergy shots and also im-
proved humoral and cellular immune responses suitable
for allergic rhinitis. Furthermore, it revealed that a physical
linkage of allergen derivatives to HBc VLPs (not simply
mixing allergen with HBc VLPs or alum) might provoke
an efficient immune response that favored a successful al-
lergy treatment.
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